Editorial Commentary

Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?

Shigeru Tanzawa, Masashi Ishihara, Terunobu Haruyama, Ryosuke Ochiai, Takahiko Sakamoto, Takeshi Honda, Shuji Ota, Yasuko Ichikawa, Kiyotaka Watanabe, Nobuhiko Seki

Abstract

Currently, three strategies for primary treatment of advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations are being investigated: epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) monotherapy, EGFR-TKI + vascular endothelial growth factor (VEGF) inhibitor combination, and EGFR-TKI + cytotoxic anticancer agent combination (Tables 1,2).

Article Options

Download Citation

Share